Influence of gut microbiota on the development of most prevalent neurodegenerative dementias and the potential effect of probiotics in elderly: A scoping review

被引:2
作者
Mateo, David [1 ]
Marques, Montse [1 ]
Domingo, Jose L. [1 ]
Torrente, Margarita [1 ,2 ,3 ,4 ]
机构
[1] Univ Rovira & Virgili, Sch Med, Lab Toxicol & Environm Hlth TecnATox, Reus, Catalonia, Spain
[2] Univ Rovira & Virgili, Fac Educ Sci & Psychol, Res Ctr Behav Assessment, Dept Psychol,CRAMC, Tarragona, Catalonia, Spain
[3] Alzheimer & other Neurocognit Disorders Assoc, Inst Lerin Neurocognit, Reus, Catalonia, Spain
[4] Univ Rovira & Virgili, Sch Med, Lab Toxicol & Environm Hlth TecnATox, Sant Llorenc 21, Reus 43201, Catalonia, Spain
关键词
Alzheimer disease; dementia; gut microbiota; Parkinson disease dementia; probiotics; CHAIN FATTY-ACIDS; PARKINSONS-DISEASE; BRAIN;
D O I
10.1002/ajmg.b.32959
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Dementia is one of today's greatest public health challenges. Its high socio-economic impact and difficulties in diagnosis and treatment are of increasing concern to an aging world population. In recent years, the study of the relationship between gut microbiota and different neurocognitive disorders has gained a considerable interest. Several studies have reported associations between gut microbiota dysbiosis and some types of dementia. Probiotics have been suggested to restore dysbiosis and to improve neurocognitive symptomatology in these dementias. Based on these previous findings, the available scientific evidence on the gut microbiota in humans affected by the most prevalent dementias, as well as the probiotic trials conducted in these patients in recent years, have been here reviewed. Decreased concentrations of short-chain fatty acids (SCFA) and other bacterial metabolites appear to play a major role in the onset of neurocognitive symptoms in Alzheimer disease (AD) and Parkinson disease dementia (PDD). Increased abundance of proinflammatory taxa could be closely related to the more severe clinical symptoms in both, as well as in Lewy Bodies dementia. Important lack of information was noted in Frontotemporal dementia behavioral variant. Moreover, geographical differences in the composition of the gut microbiota have been reported in AD. Some potential beneficial effects of probiotics in AD and PDD have been reported. However, due to the controversial results further investigations are clearly necessary.
引用
收藏
页数:17
相关论文
共 93 条
  • [1] Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial
    Agahi, Azadeh
    Hamidi, Gholam Ali
    Daneshvar, Reza
    Hamdieh, Mostafa
    Soheili, Masoud
    Alinaghipour, Azam
    Taba, Seyyed Mohammad Esmaeili
    Salami, Mahmoud
    [J]. FRONTIERS IN NEUROLOGY, 2018, 9
  • [2] Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression
    Aho, Velma T. E.
    Pereira, Pedro A. B.
    Voutilainen, Sari
    Paulin, Lars
    Pekkonen, Eero
    Auvinen, Petri
    Scheperjans, Filip
    [J]. EBIOMEDICINE, 2019, 44 : 691 - 707
  • [3] Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial (Publication with Expression of Concern)
    Akbari, Elmira
    Asemi, Zatollah
    Kakhaki, Reza Daneshvar
    Bahmani, Fereshteh
    Kouchaki, Ebrahim
    Tamtaji, Omid Reza
    Hamidi, Gholam Ali
    Salami, Mahmoud
    [J]. FRONTIERS IN AGING NEUROSCIENCE, 2016, 8
  • [4] The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults
    Aljumaah, Mashael R.
    Bhatia, Urja
    Roach, Jeffery
    Gunstad, John
    Peril, M. Andrea Azcarate
    [J]. CLINICAL NUTRITION, 2022, 41 (11) : 2565 - 2576
  • [5] Human gut microbiota: the links with dementia development
    Alkasir, Rashad
    Li, Jing
    Li, Xudong
    Jin, Miao
    Zhu, Baoli
    [J]. PROTEIN & CELL, 2017, 8 (02) : 90 - 102
  • [6] Andreadou E, 2017, J ALZHEIMERS DIS, V59, P209, DOI [10.3233/JAD-161020, 10.3233/jad-161020]
  • [7] Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial
    Arteaga-Henriquez, Gara
    Karina Rosales-Ortiz, Silvia
    Arias-Vasquez, Alejandro
    Bitter, Istvan
    Ginsberg, Ylva
    Ibanez-Jimenez, Pol
    Kilencz, Tunde
    Lavebratt, Catharina
    Matura, Silke
    Reif, Andreas
    Rethelyi, Janos
    Richarte, Vanesa
    Rommelse, Nanda
    Siegl, Anne
    Ramos-Quiroga, J. Antoni
    [J]. TRIALS, 2020, 21 (01)
  • [8] Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial
    Asaoka, Daisuke
    Xiao, Jinzhong
    Takeda, Tsutomu
    Yanagisawa, Naotake
    Yamazaki, Takahiro
    Matsubara, Yoichiro
    Sugiyama, Hideki
    Endo, Noemi
    Higa, Motoyuki
    Kasanuki, Koji
    Ichimiya, Yosuke
    Koido, Shigeo
    Ohno, Kazuya
    Bernier, Francois
    Katsumata, Noriko
    Nagahara, Akihito
    Arai, Heii
    Ohkusa, Toshifumi
    Sato, Nobuhiro
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2022, 88 (01) : 75 - 95
  • [9] Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions
    Baldini, Federico
    Hertel, Johannes
    Sandt, Estelle
    Thinnes, Cyrille C.
    Neuberger-Castillo, Lorieza
    Pavelka, Lukas
    Betsou, Fay
    Krueger, Rejko
    Thiele, Ines
    [J]. BMC BIOLOGY, 2020, 18 (01)
  • [10] Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism
    Barichella, Michela
    Severgnini, Marco
    Cilia, Roberto
    Cassani, Erica
    Bolliri, Carlotta
    Caronni, Serena
    Ferri, Valentina
    Cancello, Raffaella
    Ceccarani, Camilla
    Faierman, Samanta
    Pinelli, Giovanna
    De Bellis, Gianluca
    Zecca, Luigi
    Cereda, Emanuele
    Consolandi, Clarissa
    Pezzoli, Gianni
    [J]. MOVEMENT DISORDERS, 2019, 34 (03) : 396 - 405